Sign In
Get Clay Free →

Suggestions

    Miguel Campos Silva

    Senior Director, Strategy at OMass Therapeutics

    Miguel Campos Silva is the Senior Director of Strategy at OMass Therapeutics, a biotechnology company based in Oxford, UK. He has held this position since July 2020, where he is responsible for leading strategic planning and execution, managing partnerships, and fostering business development initiatives within the organization.13

    Professional Background

    Before joining OMass Therapeutics, Silva worked at Navigant, where he progressed through various roles from Consultant to Associate Director between 2015 and 2020. His experience at Navigant included significant responsibilities in healthcare and life sciences consulting.14

    Education

    Silva holds a Bachelor of Science (BSc) in Biochemistry from the University of St. Andrews (2009-2013) and a Master of Science (MSc) in International Health Policy (Health Economics) from the London School of Economics and Political Science (2013-2014).1

    Current Role at OMass Therapeutics

    At OMass, Silva plays a critical role in advancing the company's pipeline of therapeutics targeting rare diseases and immunological conditions. The company utilizes innovative technologies to discover medicines against validated target ecosystems.2 Silva's involvement in strategic initiatives is crucial as OMass continues to grow and expand its impact in the biotechnology sector.3

    Highlights

    Jul 20 · twitter.com
    Syncona on X: "Strategy Director at Syncona portfolio company ...
    Syncona on X: "Strategy Director at Syncona portfolio company ...

    Related Questions

    What are Miguel Campos Silva's main responsibilities at OMass Therapeutics?
    How did Miguel Campos Silva transition from consulting to strategy at OMass Therapeutics?
    What projects has Miguel Campos Silva led at OMass Therapeutics?
    What is Miguel Campos Silva's educational background and how has it influenced his career?
    How has Miguel Campos Silva's experience at Navigant prepared him for his role at OMass Therapeutics?